CAM
LPCN icon

Cormorant Asset Management’s Lipocine LPCN Stock Holding History

Cormorant Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-43,617
Closed -$2.98M – 60
2017
Q2 		$2.98M Hold
43,617
– – 0.49% 48
2017
Q1 		$2.89M Sell
43,617
-577
-1% -$37.4K 0.42% 52
2016
Q4 		$2.77M Hold
44,194
– – 0.37% 54
2016
Q3 		$3.35M Hold
44,194
– – 0.37% 61
2016
Q2 		$2.28M Buy
44,194
+4,978
+13% +$771K 0.32% 57
2016
Q1 		$6.77M Hold
39,216
– – 1.02% 35
2015
Q4 		$8.62M Hold
39,216
– – 1.03% 34
2015
Q3 		$7.89M Hold
39,216
– – 1.26% 30
2015
Q2 		$5.72M Hold
39,216
– – 0.76% 38
2015
Q1 		$4.6M Buy
+39,216
New +$4.26M 0.71% 42

Other funds holding LPCN

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cormorant Asset Management's LPCN Position: Q3 2017 in Review

Cormorant Asset Management sold out of Lipocine (LPCN) in Q3 2017, closing a stake of 43,617 shares — an estimated $2.98M sold.

Cormorant Asset Management first reported a position in LPCN in Q1 2015 and held it in 10 quarters. The position peaked at $8.62M in Q4 2015. 37 funds tracked by Wall St. Rank hold LPCN as of Q3 2017.

  • Cormorant Asset Management reported no remaining Lipocine position as of Q3 2017 after selling out during the quarter.
  • Cormorant Asset Management sold 43,617 Lipocine shares in Q3 2017, an estimated $2.98M.
  • Cormorant Asset Management first reported a position in Lipocine in Q1 2015 and held it in 10 quarters.
  • Cormorant Asset Management's Lipocine position peaked at $8.62M in Q4 2015.
  • 37 funds tracked by Wall St. Rank held Lipocine as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.